Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.
Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.
We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.
In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months. Request Insights
IN THE NEWSMay 6, 2021: Sanofi announced that it has entered into a collaboration with Stanford University School of Medicine for a period of three years. The collaboration is aimed at developing and understanding immunology and inflammation through open scientific exchange.
The global heparin market is estimated to grow with a CAGR of 4.1% during the forecast period 2021-2030. The market is further expected to garner a revenue of USD 7938.6 Million by the end of 2030, up from a revenue of USD 5340 Million in 2020. The growth of the market can primarily be attributed to the growing utilization of heparin in its various forms for the treatment of venous thromboembolism/pulmonary embolism, atrial fibrillations with embolization, peripheral arterial embolism, dialysis, surgeries, and blood transfusions among others. Moreover, the rising prevalence of venous thromboembolism worldwide is also anticipated to drive the market growth during the forecast period. According to the statistics by the U.S. Centers for Disease Control and Prevention (CDC), it has been estimated that around 60,000-100,000 Americans die of deep vein thrombosis/pulmonary embolism (DVT/PE), also known as venous thromboembolism. The statistics also stated that within 10 years, 1/3rd of the people with DVT/PE would have a recurrence of the disease. The market is also anticipated to grow on account of the growing utilization of anticoagulants for the prevention and treatment of numerous types of thromboembolic disorders, such as atrial fibrillation (AFib or AF), backed by the growing cases of such disorders worldwide. In other statistics by the U.S. CDC 175326 deaths were caused due to AFib in the year 2018 in the United States. Moreover, it has also been estimated that 12.1 Million people will have the disorder by 2030.
Regionally, the global heparin market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America region is anticipated to hold the highest market share throughout the forecast period and further attain a revenue of USD 3270.7 Million by the end of 2030, up from a revenue of USD 2188.2 Million in 2020. The market in the region is also anticipated to grow with a CAGR of 4.1% during the forecast period. The growth of the market in the region can primarily be attributed to the presence of a strong healthcare network in the region, followed by the increasing expenditure on health amongst the countries, such as the United States. According to the statistics by the World Bank, the current health expenditure as a share of GDP in the United States and Canada grew from 12.542% and 8.276% respectively in the year 2000, and is further projected to touch 16.885% and 10.79% respectively in the year 2018. CLICK TO DOWNLOAD SAMPLE REPORT
On the other hand, the market in the Asia Pacific is expected to hold the second-leading share and also grow with the highest CAGR of 4.9% during the forecast period. The market in the Asia Pacific registered a revenue of USD 1122.8 Million in 2020 and is further projected to touch USD 1802.1 Million by the end of 2030. The market in the Asia Pacific is segmented by country into China, India, Russia, Australia, Indonesia, and the Rest of Asia Pacific. Out of these, the market in China is anticipated to garner the highest market share throughout the forecast period and further grow with a CAGR of 5% during the forecast period. The market in the country is also expected to garner a revenue of USD 672.2 Million by the end of 2030 from USD 415.1 Million in 2020.
The study further incorporates Y-O-Y Growth, market opportunities, demand & supply and forecast future opportunity in North America (United States, Canada, Mexico), South America, Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
The global heparin market is segmented by product into unfractionated heparin (UFH), low molecular weight heparin (LMWH), and ultra low molecular weight heparin (ULMWH). Out of these segments, the low molecular weight heparin (LMWH) segment is anticipated to hold the highest market share throughout the forecast period and further touch a revenue of USD 5154.8 Million by the end of 2030, up from USD 3493.5 Million in 2020. The market is further segmented by route of administration into intravenous injection and subcutaneous injection, out of which, the subcutaneous injection segment is expected to hold the highest market during the forecast period. Alternatively, the intravenous injection segment is expected to grow with the highest CAGR of 4.5% during the forecast period. On the basis of application, the market is segmented into clinical trials, medical devices, and venous thromboembolism, out of which, the venous thromboembolism segment is expected to garner the highest market share throughout the forecast period and further touch a revenue of USD 7032.3 Million by 2030.
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global heparin market that are included in our report are GlaxoSmithKline plc, Pfizer Inc., Aspen Holdings, Baxter International Inc., Fresenius Kabi AG, Amphastar Pharmaceuticals, Inc., Mylan N.V., Sanofi, LEO Pharma A/S, B.Braun Melsungen AG, and others.
FREQUENTLY ASKED QUESTIONS
The growing advancements in healthcare and the rise in healthcare expenditure are some of the factors anticipated to drive the growth of the market during the forecast period.
The market is anticipated to attain a CAGR of 4.1% over the forecast period, i.e., 2021-2030.
The stringent government regulations for manufacturing heparin is one of the major factors estimated to hamper the market growth.
The market in the Asia Pacific is expected to display significant business opportunities in the future.
The major players in the market are GlaxoSmithKline plc, Pfizer Inc., Aspen Holdings, Baxter International Inc., Fresenius Kabi AG, Amphastar Pharmaceuticals, Inc, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by product, route of administration, application, and by region.
The low molecular weight heparin (LMWH) segment is anticipated to touch the largest revenue of USD 5154.8 Million by the end of 2030 and display significant growth opportunities.
Global Heparin Market TOC
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2021 Research Nester. All Rights Reserved
